Description
VICKS
Vicks Inhalant
Vicks Inhalant is a convenient nasal remedy to free you from nasal congestion. Thanks to its action, Vicks Inhalant acts:
- Clearing a blocked nose
- Promoting breathing.
Active ingredients: Each stick contains: 1.00 ml of medicinal liquor, absorbed on a piece of cellulose. ACTIVE INGREDIENTS: menthol 415.4 mg, camphor 415.4 mg.
Excipients: Siberian pine essential oil, methyl salicylate.
Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. Children up to 30 months of age. Children with a history of epilepsy or febrile convulsions.
Dosage
Vicks Inhalant is contraindicated in children up to 30 months of age (see section 4.3) and is not recommended for use in children under 6 years of age. Unscrew the cap and insert the tip of the nasal stick into one nostril, closing the other with a finger and inhale deeply. Repeat in each nostril several times a day. Do not exceed the recommended doses. The duration of treatment must not exceed 3 days.
Interactions
Vicks Inhalant should not be used in conjunction with other products (medicinal or cosmetic) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).
Side Effects for Vicks Inhalant
In general, no serious or severe side effects are expected with this product. Very rarely, cases of nasal pain have been reported. Due to the presence of camphor and menthol and in case of non-compliance with the recommended doses, there may be a risk of convulsions in children and infants. The use, especially if prolonged, of products for topical use, may cause sensitization phenomena. In this case, it is necessary to interrupt the treatment and institute appropriate therapy. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed on the website: www.agenziafarmaco.gov.it/it/responsabili dell'Agenzia Italiana del Farmaco.
